This technical upgrade for Simlandi, an adalimumab biosimilar, enables Alvotech to more than double its drug substance output per batch at its Iceland facility. By implementing targeted process development and validation, the company achieved this gain in volume without expanding its physical manufacturing footprint. Alvotech confirmed that the new methods maintain strict comparability to previously approved standards, ensuring the quality, safety, and efficacy of the final product remain unchanged despite the increased yield.